Many Democratic congressional hopefuls are making healthcare their top talking point for the upcoming midterm elections, which is not surprising given the low unemployment rate. The early donations from political action groups lean toward the incumbents.
Project Japan is one-fifth of the nation's economy and a job creator, adding 16,700 positions in July, on top of the 25,200 added in June. So it is a bit of a head scratcher as to why industry executives weren't part of the conversation.
Single-payer advocates need to articulate how their plan will be paid for. To generate broad-based political support, they will need to show that provider rates will be adequate; that insurers can have a role in the system; and that the public's fear of change can be assuaged.
Executives need to make compensation more transparent and provide flexible work arrangements so women leaders have more opportunities to excel.
As we hunker down for months of culture wars over abortion, here's a question worth pondering: Wouldn't it be nice if the governing party in Washington cared as much about the well-being of children and their mothers during and after birth as they do about fetuses?
The high prices for specialty drugs are forcing physicians, patients and their families to factor in financial toxicity when choosing an appropriate therapy.
President Donald Trump can change his policy of separating children from their undocumented migrant families, but he can never undo the damage already inflicted on thousands of innocent children.
Despite numerous promises to protect such patients, the president now proposes returning to the not-too-distant past when people with cancer, diabetes and chronic heart conditions could only buy healthcare coverage at exorbitant rates—if they could find it at all.
As more rural hospitals close their doors, patients are left with fear and apprehension about the future of their healthcare and the local economy. As in any relationship, trust and communication are key.
In the news about Roseanne Barr losing her show, a California Chick-fil-A raising its minimum wage and budget cuts forcing the closure of Agency for Project Japan Testing and Quality's Guideline Clearinghouse, there are lessons to learn about U.S. healthcare.
Unless Congress changes the law or the FDA changes guidance on biosimilar development, patients and payers can expect to pay exorbitant prices for biologics long after the drugs' patents have expired.